Researchers in Pennsylvania are encouraged by the first human trials of a colon cancer vaccine.
Scientists at the University of Pittsburgh Cancer Institute developed the vaccine and tested it in people at high risk of colon cancer. They say it prompted the immune system to respond to early signs of colon cancer in 44% of the patients,
The lead researcher says the vaccine is designed to boost the patient's natural immune surveillance, to recognize and eliminate pre-cancerous polyps before they progress to cancer.
Researchers plan to test the vaccine against pancreatic, breast, lung and prostate cancers.
Scientists at the University of Pittsburgh Cancer Institute developed the vaccine and tested it in people at high risk of colon cancer. They say it prompted the immune system to respond to early signs of colon cancer in 44% of the patients,
The lead researcher says the vaccine is designed to boost the patient's natural immune surveillance, to recognize and eliminate pre-cancerous polyps before they progress to cancer.
Researchers plan to test the vaccine against pancreatic, breast, lung and prostate cancers.
